The Pharmacokinetics of 2′- O -Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy
Restricted accessReview articleFirst published online December, 2019
The Pharmacokinetics of 2′- O -Methyl Phosphorothioate Antisense Oligonucleotides: Experiences from Developing Exon Skipping Therapies for Duchenne Muscular Dystrophy
Delivery to the target site and adversities related to off-target exposure have made the road to clinical success and approval of antisense oligonucleotide (AON) therapies challenging. Various classes of AONs have distinct chemical features and pharmacological properties. Understanding the similarities and differences in pharmacokinetics (PKs) among AON classes is important to make future development more efficient and may facilitate regulatory guidance of AON development programs. For the class of 2′-O-methyl phosphorothioate (2OMe PS) RNA AONs, most nonclinical and clinical PK data available today are derived from development of exon skipping therapies for Duchenne muscular dystrophy (DMD). While some publications have featured PK aspects of these AONs, no comprehensive overview is available to date. This article presents a detailed review of absorption, distribution, metabolism, and excretion of 2OMe PS AONs, compiled from publicly available data and previously unpublished internal data on drisapersen and related exon skipping candidates in preclinical species and DMD patients. Considerations regarding drug–drug interactions, toxicokinetics, and pharmacodynamics are also discussed. From the data presented, the picture emerges of consistent PK properties within the 2OMe PS class, predictable behavior across species, and a considerable overlap with other single-stranded PS AONs. A level of detail on muscle as a target tissue is provided, which was not previously available. Furthermore, muscle biopsy samples taken in DMD clinical trials allowed confirmation of the applicability of interspecies scaling approaches commonly applied in the absence of clinical target tissue data.
Get full access to this article
View all access options for this article.
References
1.
LundinKE, GissbergO and SmithCI. (2015). Oligonucleotide Therapies: the Past and the Present. Hum Gene Ther, 26:475–485.
2.
Crooke ST. (2017). Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther, 27:70–77.
3.
KoleR, KrainerAR and AltmanS. (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov, 11:125–140.
4.
HavensMA and HastingsML. (2016). Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res, 44:6549–6563.
5.
BumcrotD, ManoharanM, KotelianskyV and SahDW. (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol, 2:711–719.
6.
NimjeeSM, WhiteRR, BeckerRC and SullengerBA. (2017). Aptamers as Therapeutics. Annu Rev Pharmacol Toxicol, 57:61–79.
7.
Krieg AM. (2012). CpG still rocks! Update on an accidental drug. Nucleic Acid Ther, 22:77–89.
8.
BaumannV and WinklerJ. (2014). miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem, 6:1967–1984.
9.
SteinCA and CastanottoD. (2017). FDA-approved oligonucleotide therapies in 2017. Mol Ther 3; 25:1069–1075.
10.
ShenX and CoreyDR. (2018). Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res, 46:1584–1600.
11.
GodfreyC, DesviatLR, SmedsrødB, Piétri-RouxelF, DentiMA, DistererP, LorainS, Nogales-GadeaG, SardoneV, et al. (2017). Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med, 9:545–557.
12.
KhvorovaA and WattsJK. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol, 35:238–248.
13.
AnderssonP and Den BestenC. (2019). Preclinical and clinical drug-metabolism, pharmacokinetics and safety of therapeutic oligonucleotides. In: Advances in Nucleic Acid Therapeutics. AgrawalS, GaitMJ, eds. Cambridge, UK, Royal Society of Chemistry, pp 474–531.
14.
SchubertD, LevinAA, KornbrustD, BermanCL, CavagnaroJ, HenryS, SeguinR, FerrariN and ShrewsburySB. (2012). The Oligonucleotide Safety Working Group (OSWG). Nucleic Acid Ther, 22:211–212.
15.
WangJ, LonHK, LeeSL, BurckartGJ and PisetskyDS. (2015). Oligonucleotide-based drug development: considerations for clinical pharmacology and immunogenicity. Ther Innov Regul Sci, 49:861–868.
16.
LevinAA, YuRZ and GearyRS. (2008). Basic principles of pharmacokinetics of antisense oligonucleotide drugs. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed. CrookeST, ed., CRC Press, Carlsbad, CA, pp 183–215.
17.
GearyRS, NorrisD, YuR and BennettCF. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev, 87:46–51.
18.
HeemskerkH, de WinterC, van KuikP, HeuvelmansN, SabatelliP, RimessiP, BraghettaP, van OmmenGJ, de KimpeS, et al. (2010). Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther, 18:1210–1217.
19.
VerhaartIE, van Vliet-van den DoolL, SipkensJA, de KimpeSJ, KolfschotenIG, van DeutekomJC, LiefaardL, RidingsJE, HoodSR and Aartsma-RusA. (2014). The dynamics of compound, transcript, and protein effects after treatment with 2OMePS antisense oligonucleotides in mdx mice. Mol Ther Nucleic Acids, 3:e148.
20.
van DeutekomJC, JansonAA, GinjaarIB, FrankhuizenWS, Aartsma-RusA, Bremmer-BoutM, den DunnenJT, KoopK, van der KooiAJ, et al. (2007). Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med, 357:2677–2686.
21.
GoemansNM, TuliniusM, van den AkkerJT, BurmBE, EkhartPF, HeuvelmansN, HollingT, JansonAA, PlatenburgGJ, et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 21;364:1513–1522.
22.
FlaniganKM, VoitT, RosalesXQ, ServaisL, KrausJE, WardellC, MorganA, DorricottS, NakielnyJ, et al. (2014). Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Neuromuscul Disord, 24:16–24.
23.
VoitT, TopalogluH, StraubV, MuntoniF, DeconinckN, CampionG, de KimpeSJ, EagleM, GuglieriM, et al. (2014). Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol, 13:987–996.
24.
GoemansNM, TuliniusM, van den HauweM, KroksmarkAK, BuyseG, WilsonRJ, van DeutekomJC, de KimpeSJ, LourbakosA and CampionG. (2016). Long-term efficacy, safety, and pharmacokinetics of drisapersen in duchenne muscular dystrophy: results from an open-label extension study. PLoS One, 2; 11:e0161955.
25.
GoemansN, TuliniusM, KroksmarkAK, WilsonR, van den HauweM and CampionG. (2017). Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids. Neuromuscul Disord, 27:203–213.
26.
McDonaldCM, WongB, FlaniganKM, WilsonR, de KimpeS, LourbakosA, LinZ and CampionG; DEMAND V study group. (2018). Placebo-controlled phase 2 trial of drisapersen for duchenne muscular dystrophy. Ann Clin Transl Neurol, 5:913–926.
27.
GoemansN, MercuriE, BelousovaE, KomakiH, DubrovskyA, McDonaldCM, KrausJE, LourbakosA, LinZ, et al. (2018). A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Neuromuscul Disord, 28:4–15.
28.
CarpenterS and KarpatiG. (1979). Duchenne muscular dystrophy: plasma membrane loss initiates muscle cell necrosis unless it is repaired. Brain, 102:147–161.
29.
Emery AE. (2002). The muscular dystrophies. Lancet, 359:687–695.
30.
Aartsma-RusA, StraubV, HemmingsR, HaasM, Schlosser-WeberG, Stoyanova-BeninskaV, MercuriE, MuntoniF, SepodesB, VroomE and BalabanovP. (2017). Development of exon skipping therapies for Duchenne muscular dystrophy: a critical review and a perspective on the outstanding issues. Nucleic Acid Ther, 27:251–259.
31.
GearyRS, YuRZ, SiwkowskiA and LevinAA. (2008). Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed. CrookeST, ed. CRC Press, Carlsbad, CA, pp 305–326.
32.
AmantanaA and IversenPL. (2005). Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr Opin Pharmacol, 5:550–555.
33.
van de SteegE, LäppchenT, AguileraB, JansenHT, MuilwijkD, VermueR, van der HoornJW, DonatoK, RossinR, de VisserPC and VlamingMLH. (2017). Feasibility of SPECT-CT imaging to study the pharmacokinetics of antisense oligonucleotides in a mouse model of Duchenne muscular dystrophy. Nucleic Acid Ther, 27:221–231.
34.
YuRZ, GrundyJS, HenrySP, KimTW, NorrisDA, BurkeyJ, WangY, VickA and Geary.RS (2015). Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications. Mol Ther Nucleic Acids, 4:e218.
35.
JulianoRL, MingX, Carver K and BLaing. (2014). Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther 24:. 101–113.
36.
González-BarrigaA, NillessenB, KranzenJ, van KesselIDG, CroesHJE, AguileraB, de VisserPC, DatsonNA, MuldersSAM, et al. (2017). Intracellular distribution and nuclear activity of antisense oligonucleotides after unassisted uptake in myoblasts and differentiated myotubes in vitro. Nucleic Acid Ther, 27:144–158.
37.
MillerCM, WanWB, SethPP and HarrisEN. (2018). Endosomal escape of antisense oligonucleotides internalized by stabilin receptors is regulated by Rab5C and EEA1 during endosomal maturation. Nucleic Acid Ther, 28:86–96.
38.
Juliano RL. (2018). Intracellular trafficking and endosomal release of oligonucleotides: what we know and what we don't. Nucleic Acid Ther, 28:166–177.
39.
Van PuttenM, Tanganyika-de WinterC, BosgraS and Aartsma-RusA. (2019). Non-clinical exon skipping studies with 2’-O-methyl phosphorothioate antisense oligonucleotides in mdx and mdx-utrn-/- mice inspired by clinical trial results. Nucl Acid Ther, 29:92–103.
40.
MoultonHM and MoultonJD. (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta, 1798:2296–2303.
41.
PandeySN, LeeYC, YokotaT and ChenYW. (2014). Morpholino treatment improves muscle function and pathology of Pitx1 transgenic mice. Mol Ther, 22:390–396.
42.
MokriB and EngelAG. (1975). Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology, 25:1111–1120.
GoldsteinJA and McNallyEM. (2010). Mechanisms of muscle weakness in muscular dystrophy. J Gen Physiol, 136:29–34.
45.
NovakJS, HogarthMW, BoehlerJF, NearingM, VilaMC, HerediaR, FiorilloAA, ZhangA, HathouY, et al. (2017). Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. Nat Commun, 8:941.
46.
NovakJS, JaiswalJK and PartridgeTA. (2018). The macrophage as a Trojan horse for antisense oligonucleotide delivery. Expert Opin Ther Targets, 22:463–466.
47.
AokiY, NagataT, YokotaT, NakamuraA, WoodMJ, PartridgeT and TakedaS. (2013). Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice. Hum Mol Genet, 22:4914–4928.
48.
CirakS, Arechavala-GomezaV, GuglieriM, FengL, TorelliS, AnthonyK, AbbsS, GarraldaME, BourkeJ, et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 13;378:595–605.
49.
VilaMC, KlimekMB, NovakJS, RayavarapuS, UaesoontrachoonK, BoehlerJF, FiorilloAA, HogarthMW, ZhangA, et al. (2015). Elusive sources of variability of dystrophin rescue by exon skipping. Skelet Muscle, 5:44.
50.
HeemskerkHA, de WinterCL, de KimpeSJ, van Kuik-RomeijnP, HeuvelmansN, PlatenburgGJ, van OmmenGJ, van DeutekomJC and Aartsma-RusA (2009). In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med, 11:257–266.
51.
MercuriE, DarrasBT, ChiribogaCA, DayJW, CampbellC, ConnollyAM, IannacconeST, KirschnerJ, KuntzNL, et al. (2018). Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med, 378:625–635.
52.
KordasiewiczHB, StanekLM, WancewiczEV, MazurC, McAlonisMM, PytelKA, ArtatesJW, WeissA, ChengSH, et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74:1031–1044.
53.
DatsonNA, González-BarrigaA, KourkoutaE, WeijR, van de GiessenJ, MuldersS, KontkanenO, HeikkinenT, LehtimäkiK and van DeutekomJC. (2017). The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain. PLoS One, 12:e0171127.
54.
de SmetMD, MeenkenCJ and van den HornGJ. (1999). Fomivirsen—a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm, 7:189–198.
55.
Vinores SA. (2006). Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomedicine, 1:263–268.
56.
VerhaartIE, Tanganyika-de WinterCL, KarnaoukhTG, KolfschotenIG, de KimpeSJ, van DeutekomJC and Aartsma-RusA. (2013). Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice. Nucleic Acid Ther, 23:228–237.
57.
EderPS, DeVineRJ, DagleJM and WalderJA. (1991). Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3’ exonuclease in plasma. Antisense Res Dev, 1:141–151.
58.
GilarM, BelenkyA, BudmanY, SmisekDL and CohenAS. (1998). Impact of 3'-exonuclease stereoselectivity on the kinetics of phosphorothioate oligonucleotide metabolism. Antisense Nucleic Acid Drug Dev, 8:35–42.
59.
Levin AA. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta, 1489:69–84.
60.
EcksteinF. (2000). Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev, 10:117–121.
61.
EMA (2012). Guideline on the investigation of drug interactions. CPMP/EWP/560/95/Rev. 1, Committee for Human Medicinal Products (CHMP), June 2012.
62.
FDA (2017). In Vitro Metabolism and Transporter-Mediated Drug-Drug Interaction Studies. Draft Guidance for Industry. FDA CDER, October 2017.
63.
ShemeshCS, YuRZ, WarrenMS, LiuM, JahicM, NicholsB, PostN, LinS, NorrisDA, HurhE, HuangJ, WatanabeT, HenrySP and WangY. (2017). Assessment of the drug interaction potential of unconjugated and GalNAc3-conjugated 2'-MOE-ASOs. Mol Ther Nucleic Acids, 9:34–47.
64.
KazmiF, YerinoP, McCoyC, ParkinsonA, BuckleyDB and OgilvieBW. (2018). An assessment of the in vitro inhibition of cytochrome P450 enzymes, UDP-glucuronosyltransferases, and transporters by phosphodiester- or phosphorothioate-linked oligonucleotides. Drug Metab Dispos, 46:1066–1074.
65.
AdjeiAA, DyGK, ErlichmanC, ReidJM, SloanJA, PitotHC, AlbertsSR, GoldbergRM, HansonLJ, et al. (2003). A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res, 9:115–123.
66.
Villalona-CaleroMA, RitchP, FigueroaJA, OttersonGA, BeltR, DowE, GeorgeS, LeonardoJ, McCachrenS, et al. (2004). A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res, 10(Pt 1):6086–6093.
67.
GearyRS, BradleyJD, WatanabeT, KwonY, WedelM, van LierJJ and vanVlietAA. (2006). Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet, 45:789–801.
68.
YuRZ, GearyRS, FlaimJD, RileyGC, TribbleDL, vanVlietAA and WedelMK. (2009). Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet, 48:39–50.
69.
LiZ, HardML, GrundyJS, SinghT, von MoltkeLL and BoltjeI. (2014). Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. J Cardiovasc Pharmacol, 64:164–171.
70.
YuRZ, WarrenMS, WatanabeT, NicholsB, JahicM, HuangJ, BurkeyJ, GearyRS, HenrySP and WangY. (2016). Lack of interactions between an antisense oligonucleotide with 2'-O-(2-methoxyethyl) modifications and major drug transporters. Nucleic Acid Ther, 26:111–117.
71.
HeubergerJ, SchmidtS and DerendorfH. (2013). When is protein binding important? J Pharm Sci, 102:3458–3467.
72.
BosgraS, van de SteegE, VlamingML, VerhoeckxKC, HuismanMT, VerweiM and WortelboerHM. (2014). Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. Eur J Pharm Sci, 65:156–166.
73.
SrinivasanSK, TewaryHK and IversenPL. (1995). Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev, 5:131–139.
74.
WatanabeTA, GearyRS and LevinAA. (2006). Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides, 16:169–180.
75.
JasonTL, KoropatnickJ and BergRW. (2004). Toxicology of antisense therapeutics. Toxicol Appl Pharmacol, 201:66–83.
76.
HenrySP, KimTW, Kramer-SticklandK, ZanardiTA, FeyRA and LevinAA. (2008). Toxicologic properties of 2'-methoxyethyl chimeric antisense inhibitors in animals and man. In: Antisense Drug Technology: Principles, Strategies and Applications, 2nd ed. CrookeST, ed. CRC Press, Carlsbad, CA, pp 327–363.
77.
YoshidaT, NaitoY, SasakiK, UchidaE, SatoY, NaitoM, KawanishiT, ObikaS and InoueT. (2018). Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences. Genes Cells, 23:448–455.
78.
BurelSA, HartCE, CauntayP, HsiaoJ, MachemerT, KatzM, WattA, BuiHH, YounisH, et al. (2016). Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res 18;44:2093–2109.
HagedornPH, PontoppidanM, BisgaardTS, BerreraM, DieckmannA, EbelingM, MøllerMR, HudlebuschH, JensenML, et al. (2018). Identifying and avoiding off-target effects of RNase H-dependent antisense oligonucleotides in mice. Nucleic Acids Res, 46:5366–5380.
81.
LinX, RuanX, AndersonMG, McDowellJA, KroegerPE, FesikSW and ShenY. (2005). siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res, 33:4527–4535.
82.
JacksonAL, BurchardJ, SchelterJ, ChauBN, ClearyM, LimL and LinsleyPS. (2006). Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA, 12:1179–1187.
83.
KamolaPJ, KitsonJD, TurnerG, MaratouK, ErikssonS, PanjwaniA, WarnockLC, Douillard GuillouxGA, MooresK, et al. (2015). In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization. Nucleic Acids Res, 43:8638–8650.
84.
KamolaPJ, MaratouK, WilsonPA, RushK, MullaneyT, McKevittT, EvansP, RidingsJ, ChowdhuryP, et al. (2017). Strategies for in vivo screening and mitigation of hepatotoxicity associated with antisense drugs. Mol Ther Nucleic Acids, 8:383–394.
85.
DieckmannA, HagedornPH, BurkiY, BrügmannC, BerreraM, EbelingM, SingerT and SchulerF. (2018). A sensitive in vitro approach to assess the hybridization-dependent toxic potential of high affinity Gapmer oligonucleotides. Mol Ther Nucleic Acids, 10:45–54.
86.
KriegAM, YiAK, MatsonS, WaldschmidtTJ, BishopGA, TeasdaleR, KoretzkyGA and KlinmanDM. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374:546–549.
87.
HilhorstN, Spanoudi-KitrimiI, GoemansN and MorrenMA. (2019). Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. Eur J Pediatr, 178:253–258.
88.
FrazierKS, SobryC, DerrV, AdamsMJ, den BestenC, de KimpeS, FrancisI, GalesTL, HaworthR, et al. (2014). Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide. Toxicol Pathol, 42:923–935.
89.
Frazier KS. (2015). Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective. Toxicol Pathol, 43:78–89.
90.
HenrySP, NovotnyW, LeedsJ, AulettaC and KornbrustDJ. (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev, 7:503–510.
91.
SheehanJP and LanHC. (1998). Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex. Blood, 92:1617–1625.
92.
HenrySP, GiclasPC, LeedsJ, PangburnM, AulettaC, LevinAA and KornbrustDJ. (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther, 281:810–816.
93.
HenrySP, JagelsMA, HugliTE, ManaliliS, GearyRS, GiclasPC and LevinAA. (2014). Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther, 24:326–335.
94.
ShenL, Frazer-AbelA, ReynoldsPR, GiclasPC, ChappellA, PangburnMK, YounisH and HenrySP. (2014). Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. J Pharmacol Exp Ther, 351:709–717.
95.
CrookeST, BakerBF, KwohTJ, ChengW, SchulzDJ, XiaS, SalgadoN, BuiHH, HartCE, et al. (2016). Integrated safety assessment of 2'-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther, 24:1771–1782.
96.
HenrySP, NarayananP, ShenL, BhanotS, YounisHS and BurelSA. (2017). Assessment of the effects of 2'-methoxyethyl antisense oligonucleotides on platelet count in cynomolgus nonhuman primates. Nucleic Acid Ther, 27:197–208.
97.
CrookeST, BakerBF, WitztumJL, KwohTJ, PhamNC, SalgadoN, McEvoyBW, ChengW, HughesSG, BhanotS and GearyRS. (2017). The effects of 2'-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther, J27:121–129.
98.
ChiX, GattiP and PapoianT. (2017). Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today, 22:823–833.
99.
LorenzP, MisteliT, BakerBF, BennettCF and SpectorDL. (2000). Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res, 28:582–592.
100.
Juliano RL. (2016). The delivery of therapeutic oligonucleotides. Nucleic Acids Res, 44:6518–6548.
101.
Jansson-LöfmarkR and GennemarkP. (2018). Inferring half-lives at the effect site of oligonucleotide drugs. Nucleic Acid Ther, 28:319–325.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
